Health Stock on the Rise
This stock could be a major success story in 2021.
Here's why.
Anna Mowry, insider at Nautilus Biotechnology
Anna Mowry Insider Alerts

Get notified the next time Anna Mowry buys or sells Nautilus Biotechnology stock. Enter your email address below to get our daily insider buying and selling report.

Anna Mowry Insider Information

Anna is an experienced finance and business leader who joins Nautilus from Igneous where she served as VP of Finance and Operations with responsibility for finance, accounting, people, legal, and operations. Previously, Anna held a variety of roles at companies including Amazon Web Services and Isilon Systems, where she ultimately led the finance and sales operations organization. Anna has a BS in Biochemistry from Western Washington University and started her career at the Fred Hutchinson Cancer Research Institute. She earned her MBA from the University of Washington, leading her into a variety of finance and business roles of escalating responsibility.

How do I contact Anna Mowry?

The corporate mailing address for Ms. Mowry and other Nautilus Biotechnology executives is 51 ASTOR PLACE 10TH FLOOR, NEW YORK NY, 10003.

Has Anna Mowry been buying or selling shares of Nautilus Biotechnology?

Anna Mowry has not been actively trading shares of Nautilus Biotechnology during the last quarter. Most recently, on Thursday, August 12th, Anna Mowry bought 17,500 shares of Nautilus Biotechnology stock. The stock was acquired at an average cost of $7.71 per share, with a total value of $134,925.00.

Who are Nautilus Biotechnology's active insiders?

Nautilus Biotechnology's insider roster includes Matthew Mcilwain (Director), Anna Mowry (CFO), Anna Mowry (CFO), and Matthew Murphy (General Counsel).

Are insiders buying or selling shares of Nautilus Biotechnology?

In the last year, Nautilus Biotechnology insiders bought shares 6 times. They purchased a total of 5,654,840 shares worth more than $55,967,833.63. The most recent insider tranaction occured on November, 15th when Director Matthew S Mcilwain bought 100,000 shares worth more than $530,000.00.

Information on this page was last updated on 11/15/2021.

Anna Mowry Insider Trading History at Nautilus Biotechnology

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/12/2021Buy17,500$7.71$134,925.00View SEC Filing Icon  
See Full Table

Anna Mowry Buying and Selling Activity at Nautilus Biotechnology

This chart shows Anna Mowry's buying and selling at Nautilus Biotechnology by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Nautilus Biotechnology Company Overview

Nautilus Biotechnology logo
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating platform technology for quantifying and unlocking the complexity of the proteome. It operates Nautilus Proteomic Analysis Platform, an integrated single-molecule protein analysis platform that leverages a nanofabricated, large-scale, single-molecule protein array, multi-cycle imaging, and machine learning analysis to potentially identify and quantify the proteome. The company was founded in 2016 and is headquartered in Seattle, Washington.
Read More

Today's Range

Now: $4.57
Low: $4.57
High: $4.95

50 Day Range

MA: $5.61
Low: $4.57
High: $6.97

2 Week Range

Now: $4.57
Low: $4.43
High: $25.89


404,376 shs

Average Volume

467,494 shs

Market Capitalization

$567.44 million

P/E Ratio


Dividend Yield



Health Stock on the Rise
This stock could be a major success story in 2021.
Here's why.